Hypoglycaemia: difference between revisions
Diff·revision 14 → 15·19:50, 14 Jun 2025
Difference between revision 14 and revision 15 of Hypoglycaemia. 5 lines changed; the page grew by 642 bytes.
| Revision 14 — 21:26, 8 May 2025 NauseaNoor (talk) clarify that dose-dependence is reported for some effects and not others 3,775 bytes +32 | Revision 15 — 19:50, 14 Jun 2025 SVG_Solomon (talk) expand §Why glucose dependence matters 4,417 bytes +642 | ||
|---|---|---|---|
| 32 | Symptoms are conventionally divided into adrenergic — tremor, sweating, palpitation — and neuroglycopenic — confusion, difficulty concentrating, visual change. Adrenergic symptoms are the warning, and it is those that impaired awareness removes.{{r|ada2024}} | 32 | Symptoms are conventionally divided into adrenergic — tremor, sweating, palpitation — and neuroglycopenic — confusion, difficulty concentrating, visual change. Adrenergic symptoms are the warning, and it is those that impaired awareness removes.{{r|ada2024}} |
| 33 | 33 | ||
| + | 34 | == In the context of this wiki == | |
| + | 35 | Compounds discussed here that are sold for research use are not approved for human administration, and this article describes hypoglycaemia as it appears in the clinical literature rather than as advice for any use.{{r|ada2024}} | |
| + | 36 | ||
| + | 37 | The relevant general point is that the glucose-dependence argument is a property of receptor pharmacology and does not extend to a preparation of unknown identity or content. A material whose actual peptide mass is unknown — see [[Peptide content]] and [[Underfilling]] — cannot be reasoned about pharmacologically at all, because the exposure is unknown.{{r|drucker2018}} | |
| + | 38 | ||
| 34 | == References == | 39 | == References == |
| 35 | {{reflist}} | 40 | {{reflist}} |